Clinical Trials Browser

Phase 2 × Interventional × 30 days × Clear all

NCT00761618 2026-04-16

Intrapleural Catheter Daily Versus Three Times a Week Drainage

Phase 2 Active not recruiting

Pleural Effusion, Pleural Effusion, Malignant

NCT01709292 2026-04-16

Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer

Phase 2 Active not recruiting

EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms

NCT01857934 2026-04-16

Therapy for Children With Advanced Stage Neuroblastoma

Phase 2 Completed

153 enrolled 12 charts

Neuroblastoma

NCT02128906 2026-04-16

Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design

Phase 2 Recruiting

Carcinoma, Squamous Cell, Laryngeal Diseases

NCT02131584 2026-04-16

Ruxolitinib Phosphate in Reducing Fatigue in Patients With Chronic Lymphocytic Leukemia

Phase 2 Active not recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02934568 2026-04-16

Ribociclib (LEE011) Rollover Study for Continued Access

Phase 2 Active not recruiting

Other solid neoplasm

Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies

NCT03110978 2026-04-16

Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer

Phase 2 Active not recruiting

EndocrineThoracic

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma, Neuroendocrine

NCT03259867 2026-04-16

TATE-PD1

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular, Stomach Neoplasms, Disease Progression

NCT03418038 2026-04-16

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Hodgkin Disease, Lymphoma, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large B-Cell, Diffuse

NCT03574792 2026-04-16

Gabapentin, Methadone, and Oxycodone With or Without Venlafaxine Hydrochloride in Managing Pain in Participants With Stage II-IV Squamous Cell Head and Neck Cancer Undergoing Chemoradiation Therapy

Phase 2 Completed

62 enrolled 10 charts

DermatologicHead & Neck

Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8

NCT03618550 2026-04-16

Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

Phase 2 Recruiting

Hodgkin Disease, Recurrence

NCT03634241 2026-04-16

Pembrolizumab in Preventing Lung Cancer in Patients With Stage I-II Non-Small Cell Lung Cancer or High-Risk Pulmonary Nodules, the IMPRINT-Lung Study

Phase 2 Completed

45 enrolled 9 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03866382 2026-04-16

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Phase 2 Recruiting

Urachal adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Penile Neoplasms, Prostatic Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

NCT04189757 2026-04-16

Acalabrutinib for the Treatment of Ibrutinib-Intolerant Mantle Cell Lymphoma

Phase 2 Active not recruiting

Lymphoma, Mantle-Cell

NCT04237623 2026-04-16

GM-CSF With Post-Transplant Cyclophosphamide

Phase 2 Recruiting

Transplant-Related Hematologic Malignancy

NCT04316546 2026-04-16

MK-7075 (Miransertib) in Proteus Syndrome

Phase 2 Recruiting

Proteus Syndrome

NCT04355156 2026-04-16

AXMUS-C

Phase 2 Completed

52 enrolled 12 charts

Gastrointestinal

Colorectal Neoplasms

NCT04552288 2026-04-16

Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies

Phase 2 Active not recruiting

51 enrolled 8 charts

Other hematologic neoplasm

Hematologic Neoplasms

NCT04606446 2026-04-16

KAT6

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT04661150 2026-04-16

A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction

Phase 2 Active not recruiting

42 enrolled 9 charts

Gastrointestinal

Stomach Neoplasms

NCT04665739 2026-04-16

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

Phase 2 Recruiting

Advanced Lung Neuroendocrine Tumor

NCT04671667 2026-04-16

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

Phase 2 Recruiting

Squamous Cell Carcinoma of Head and Neck

NCT04701476 2026-04-16

TATE and Pembrolizumab (MK3475) in mCRC and NSCLC

Phase 2 Recruiting

GastrointestinalThoracic

Lung Neoplasms, Colorectal Neoplasms

NCT04789681 2026-04-16

Canakinumab for the Prevention of Lung Cancer, the Can-Prevent-Lung Trial

Phase 2 Recruiting

Lung Neoplasms

NCT04879121 2026-04-16

Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors

Phase 2 Recruiting

Neoplasm Metastasis

NCT04940286 2026-04-16

Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer

Phase 2 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT05013892 2026-04-16

NTS-WBRT in Brain Metastases

Phase 2 Recruiting

Brain Neoplasms

NCT05026983 2026-04-16

Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases

Phase 2 Recruiting

Melanoma

NCT05064280 2026-04-16

Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases

Phase 2 Recruiting

Brain Neoplasms, Neoplasms

NCT05123807 2026-04-16

Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)

Phase 2 Recruiting

Ovarian Neoplasms

NCT05398861 2026-04-16

Utidelone Combined With Bevacizumab in the Treatment of ≥ 2 Lines of HER-2 Negative Advanced Breast Cancer

Phase 2 Recruiting

HER-2 Negative Breast Cancer

NCT05456698 2026-04-16

Efficacy and Safety of Inotuzumab Ozogamicin in Treating Adult Patients With Ph Negative ALL With Minimal Residual Disease Positive After Induction Chemotherapy

Phase 2 Active not recruiting

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05498220 2026-04-16

Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Phase 2 Terminated

5 enrolled 13 charts

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05534438 2026-04-16

A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT05537896 2026-04-16

Prospective Evaluation of Xerava Prophylaxis in Hematological Malignancy Patients With Prolonged Neutropenia

Phase 2 Recruiting

Other hematologic neoplasm

Neutropenia, Hematologic Neoplasms

NCT05554393 2026-04-16

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

Phase 2 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05564377 2026-04-16

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Phase 2 Recruiting

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

NCT05616650 2026-04-16

Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor

Phase 2 Recruiting

Prostatic Neoplasms

NCT05638295 2026-04-16

Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)

Phase 2 Recruiting

Neoplasm Metastasis

NCT05749588 2026-04-16

FUSCC Refractory TNBC Platform Study (FUTURE2.0)

Phase 2 Recruiting

Triple Negative Breast Neoplasms

NCT05789485 2026-04-16

A Study on the Effects of Exercise on Side Effects From Treatment for Gastrointestinal Cancers

Phase 2 Recruiting

Gastrointestinal

Gastrointestinal Neoplasms, Motor Activity

NCT05925530 2026-04-16

MDT-BRIDGE

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05967182 2026-04-16

A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma

Phase 2 Recruiting

Gastrointestinal

Cholangiocarcinoma

NCT06083922 2026-04-16

A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)

Phase 2 Recruiting

Multiple Myeloma

NCT06126276 2026-04-16

Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)

Phase 2 Recruiting

Other solid neoplasm

Malignant Female Reproductive System Neoplasm

NCT06179303 2026-04-16

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Phase 2 Recruiting

Anatomic Stage III Breast Cancer AJCC v8

NCT06200155 2026-04-16

Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy

Phase 2 Recruiting

Anxiety Disorders, Depression

NCT06317662 2026-04-16

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute

NCT06347705 2026-04-16

A Study of 2141-V11 in Combination With Standard Treatments in People With Prostate Cancer

Phase 2 Recruiting

Prostatic Neoplasms

NCT06406465 2026-04-16

A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

Phase 2 Recruiting

Carcinoma, Neuroendocrine, Neuroendocrine Tumors